SML0309
Sodium phenylbutyrate
≥98% (HPLC), histone deacetylase inhibitor, powder
Synonyme(s) :
4-PBA, 4-Phenylbutyric acid, 4-phenylbutyrate, Buphenyl, Sodium 4-phenylbutyrate, TriButyrate
Se connecter pour consulter les tarifs organisationnels et contractuels.
Sélectionner une taille de conditionnement
Changer de vue
A propos de cet article
Formule empirique (notation de Hill) :
C10H11NaO2
Numéro CAS:
Poids moléculaire :
186.18
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
MDL number:
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aiderNom du produit
Sodium phenylbutyrate, ≥98% (HPLC)
Quality Level
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
H2O: ≥5 mg/mL
storage temp.
room temp
SMILES string
[Na+].[O-]C(=O)CCCc1ccccc1
InChI
1S/C10H12O2.Na/c11-10(12)8-4-7-9-5-2-1-3-6-9;/h1-3,5-6H,4,7-8H2,(H,11,12);/q;+1/p-1
InChI key
VPZRWNZGLKXFOE-UHFFFAOYSA-M
General description
Sodium phenylbutyrate stimulates urinary nitrogen excretion. It is a prodrug, which undergoes β-oxidation to phenylacetate. Sodium phenylbutyrate is used to treat urea cycle disorder. It might be associated with menstrual dysfunction, amenorrhea and painful mucositis of the esophagus and stomach.
Application
Sodium phenylbutyrate has been used as an endoplasmic reticulum (ER) stress inhibitor to study the role of ER stress in the expression of betatrophin.
Biochem/physiol Actions
Sodium phenylbutyrate is a histone deacetylase inhibitor.
Features and Benefits
This compound is a featured product for Gene Regulation research. Click here to discover more featured Gene Regulation products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
Classe de stockage
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Faites votre choix parmi les versions les plus récentes :
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Phase 2 comparison of a novel ammonia scavenging agent with sodium phenylbutyrate in patients with urea cycle disorders: safety, pharmacokinetics and ammonia control
Lee B, et al.
Molecular Genetics and Metabolism, 100(3), 221-228 (2010)
Association between betatrophin/ANGPTL8 and non-alcoholic fatty liver disease: animal and human studies
Lee YH, et al.
Scientific Reports, 6(3), 24013-24013 (2016)
Advances in Clinical Chemistry, Volume 17 (2014)